Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0BW4G
|
||||
| Former ID |
DIB020666
|
||||
| Drug Name |
PDGF receptor tyrosine kinase inhibitor III
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [526865] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C27H27N5O4
|
||||
| InChI |
InChI=1S/C27H27N5O4/c1-34-24-16-22-23(17-25(24)35-2)28-18-29-26(22)31-12-14-32(15-13-31)27(33)30-19-8-10-21(11-9-19)36-20-6-4-3-5-7-20/h3-11,16-18H,12-15H2,1-2H3,(H,30,33)
|
||||
| InChIKey |
INTPTKHSGKBHHW-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Beta platelet-derived growth factor receptor | Target Info | Inhibitor | [526865] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Ras signaling pathway | |||||
| Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Gap junction | |||||
| Regulation of actin cytoskeleton | |||||
| HTLV-I infection | |||||
| Pathways in cancer | |||||
| MicroRNAs in cancer | |||||
| Glioma | |||||
| Prostate cancer | |||||
| Melanoma | |||||
| Central carbon metabolism in cancer | |||||
| Choline metabolism in cancer | |||||
| PANTHER Pathway | Angiogenesis | ||||
| PDGF signaling pathway | |||||
| Pathway Interaction Database | Signaling events mediated by PTP1B | ||||
| Beta3 integrin cell surface interactions | |||||
| S1P3 pathway | |||||
| Nectin adhesion pathway | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| PDGFR-beta signaling pathway | |||||
| Validated targets of C-MYC transcriptional repression | |||||
| PDGF receptor signaling network | |||||
| References | |||||
| Ref 526865 | Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives. J Med Chem. 2003 Nov 6;46(23):4910-25. | ||||
| Ref 526865 | Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives. J Med Chem. 2003 Nov 6;46(23):4910-25. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.